Bionomics (BNO)

Download button icon Download

Bionomics (BNO): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY


The opening and closing bar positions can add depth to assess whether buyers of sellers commitment is changing and thus which side is in control at the close of the trading session.

Calculation: Open Today Versus Close Today (OTCT):
1) If the market opens near the low and closes near the high the buyers have had control during the entire day;
2) If the market opens near the high and closes near the low the sellers have had control during the entire day;
3) If the market opens near one extreme of the range and closes near the middle of the range the side who started in control has lost commitment;
4) If the market opens near one extreme and closes near the same extreme the side who started in control has lost control;
5) If the market opens near the middle of the range and closes near one extreme control has swung to the buyers;
6) If the close is near the high and if the close is near the low the control has swung to the sellers;
7) If the market opens near the middle of the range and closes similarly neither side is strongly committed;


PROFILE: Bionomics (BNO.AX)


Stock Exchange: ASX
Company: Bionomics
Ticker Codes: | BNO.AX | ASX:BNO |

About Bionomics (ASX:BNO):

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Top 10:

Open vs Close

Download button icon Download
Company Close Change (%) Volume Value Signal
BFC Beston Global Food 0.19 12.1 205,454 0 NEUTRAL
PNR Pacific Niugini Minerals 0.18 9.1 888,016 0 NEUTRAL
IFT Infratil 3.35 6.3 787 0 NEUTRAL
RCT Reef Casino 3.3 2.5 9,698 0 NEUTRAL
WAF West African Resources 0.29 1.8 488,020 0 NEUTRAL
PHI Phileo Australia 14 1.8 1,000 0 NEUTRAL
TPM Tpg Telecom 7.46 1.6 1,237,782 0 NEUTRAL
AIA Auckland International Airport 6.7 1.1 118,936 0 NEUTRAL
HOM Homeloans 0.54 0.9 42,500 0 NEUTRAL
FXJ Fairfax 0.64 0.8 11,946,032 0 NEUTRAL
back to top